Health Updated on Apr 21, 2021 9:32 AM EDT — Published on Apr 21, 2021 8:00 AM EDT
Robin Hauser, a
pediatrician in Tampa, Florida, got COVID in February. What separates her from
the vast majority of the tens of millions of other Americans who have come down
with the virus is this: She got sick seven weeks after her second dose of the Pfizer-BioNTech
vaccine. “I was shocked,” said Hauser. “I thought: ‘What the heck? How did that
happen?’ I now tell everyone, including my colleagues, not to let their guard
down after the vaccine.”
As more Americans every
day are inoculated, a tiny but growing number are contending with the
disturbing experience of getting COVID despite having had one shot, or even
two. In data released Thursday, the Centers for Disease Control and Prevention reported that at
least 5,800 people had fallen ill or tested positive for the coronavirus two
weeks or more after they completed both doses of the Pfizer-BioNTech or Moderna
vaccine.
A total of about 78 million Americans are now fully vaccinated. These
so-called breakthrough infections occurred among people of all ages. Just over
40% were in people age 60 or older, and 65% occurred in women. Twenty-nine
percent of infected people reported no symptoms, but 7% were hospitalized and
just over 1%, 74 people, died, according to the CDC.
Public health officials
have said breakthrough infections were expected, since manufacturers have
warned loudly and often that the vaccines are not 100% protective. The Pfizer
and Moderna versions have consistently been shown to be above 90% effective,
most recently for at least six months. Studies have also shown they are nearly
100% effective at ensuring that the small fraction of vaccinated patients who
do contract the virus will not get severe cases or require hospitalization.
Still, people are
usually shocked and befuddled when they become the rare breakthrough victim.
After months of fear and taking precautions to avoid contracting COVID, they
felt safe once they got their shots. Hauser, 52, had stayed home from work to
care for her kids, ages 21 and 16, both of whom had contracted the virus. She
was confident she was protected. She was also taking care of her father, who
has cancer. “It’s a minor miracle that I didn’t infect him before I realized I,
too, was sick,” Hauser said. In keeping with the virus’s fickle behavior,
Hauser’s husband, Brian, who had not yet been vaccinated, also never got
infected.
Masha Gessen, a staff
writer for The New Yorker, completed the two-shot process in mid-February. A
month later, Gessen fell ill and tested positive after both Gessen’s son and
partner, Julia Loktev, had weathered bouts of COVID. The experience was
“unsettling, even a bit traumatic,” Gessen said. Loktev’s illness occurred six
days after her first dose.
“The psychological effect of getting the virus after a year of being very, very careful and getting vaccinated got to me,” Gessen, 54, said in an interview with KHN. “It took me about three weeks to feel back to normal.” Gessen wrote about the experience this month in The New Yorker.
Dr. Kami Kim, director
of the infectious disease and international medicine division at the University
of South Florida in Tampa, said physicians are equally disturbed when these
cases crop up. “All this, while anticipated, is definitely confusing and frustrating
for people, both doctors and patients. We are all learning on the go and making
judgments about what’s best for our patients — and ourselves,” Kim said.
Vaccine manufacturers
said the number of breakthrough cases reported by the CDC was not surprising. Moderna’s
latest analysis of its vaccine clinical trial data shows 900 people got COVID
after being vaccinated, consistent with 90% or more efficacy for the vaccine,
company spokesperson Colleen Hussey said.
Pfizer spokesperson
Jerica Pitts said the company would monitor trial participants for two years
after their second dose to learn more about the Pfizer vaccine’s protection
against COVID. In their reporting, the CDC is defining a breakthrough case
strictly as illness or a positive test two weeks or more after full
vaccination. But tens of thousands of people who have had a first shot or are
short of two weeks after their second shot are also getting infected.
Pfizer and Moderna
report data showing up to 80% protection from infection two weeks or so after
the first shot. But most experts believe protection ranges widely, from 50% to
80%, depending on the length of time after the shot and the individual
variation that exists with any vaccine. The second shot boosts immunity further
but not for a few days, at minimum, and then builds over two weeks. And again,
this could vary from person to person.
Leslie Fratkin, 60, a
freelance photographer in New York City, got her second Pfizer dose March 12. So she was surprised
when clear symptoms of COVID showed up March 24 and she was quite sick at home for three
days. “You can’t print the words I uttered at the time,” she said.
The CDC advises people
who get COVID after a first shot to get the second dose soon after recovery,
with no minimum wait time specified. That’s a change from prevalent advice back
in December and January, when some state health departments advised people to
wait 90 days after a bout of COVID to get a first or second shot, and
especially a second shot.
Driving this important
change is mounting evidence from studies and experience indicating that
immunity to infection conferred by the vaccines is stronger and possibly more
“stable” over time than immunity derived from COVID infection.
Michael Osterholm,
director of the Center for Infectious Disease
Research and Policy at the University of Minnesota in
Minneapolis, said further research and better public health guidance are
urgently needed. For example, is a second dose even needed for people who get
COVID after the first dose, or does the infection itself serve as enough of an
immune system booster? And if a second shot is recommended, what’s the optimal
waiting period before getting it? “These are important practical questions that
need to be prioritized,” Osterholm said. “We are sort of flying blind now.”
Other countries have
handled the second dose rollout differently. In the U.K., health authorities
delayed it up to 12 weeks, to stretch vaccine supply and prioritize getting at
least one shot into more people’s arms more quickly. In Canada, a government
vaccine advisory committee recommended April 7 that second doses be delayed up to four
months.
At two press briefings
this month, Dr. Anthony Fauci, director of the National Institute of Allergy
and Infectious Diseases and a COVID adviser to President Joe Biden, said that
the number of breakthrough cases in the U.S. so far is not cause for alarm and
that the administration will continue to monitor these instances closely.
One important line of
investigation is how big a role variants or mutated versions of the initial
coronavirus play in these breakthrough cases. Research suggests the current
vaccines may be somewhat less effective against some new variants. Martha
Sharan, a CDC spokesperson, said the agency is now urging states to use genetic
sequencing to test virus specimens from patients with breakthrough cases to
identify variants. In Washington state, for instance, eight variants were
detected in the genetic sequencing of nine breakout cases reported
through April
3.
Today the Biden
administration announced $1.7 billion in spending would
be directed from the COVID relief bill to help the CDC, states and other
jurisdictions more effectively detect and track variants by scaling genomic
sequencing efforts. The CDC also has launched a national COVID vaccine
breakthrough database in which state health departments can store and manage
data. “We are behind on sequencing samples,” said Osterholm. “That will give us
valuable information.”
KHN senior correspondent JoNel
Aleccia contributed to this story. Steven Findlay, a KHN
contributing reporter, came down with COVID 30 days after his first dose and 24
hours after his second dose. Kaiser Health News (KHN) is a national
health policy news service. It is an editorially independent program of
the Henry J. Kaiser Family Foundation which is not affiliated
with Kaiser Permanente.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.